Breast最新文献

{"title":"Treatment of oligometastatic breast cancer: The role of patient selection.","authors":"Riccardo Ray Colciago, Maria Carmen De Santis, Carlotta Giandini, Maria Grazia Carnevale, Serena Di Cosimo","doi":"10.1016/j.breast.2024.103839","DOIUrl":"https://doi.org/10.1016/j.breast.2024.103839","url":null,"abstract":"<p><p>Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT). This has become a valid ablative treatment option for OMD patients. However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients. We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"103839"},"PeriodicalIF":5.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050","authors":"Mengxia Fu ,&nbsp;Zhiming Peng ,&nbsp;Min Wu ,&nbsp;Dapeng Lv ,&nbsp;Yanping Li ,&nbsp;Shuzhen Lyu","doi":"10.1016/j.breast.2024.103835","DOIUrl":"10.1016/j.breast.2024.103835","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer remains a significant health concern in Asia. This study seeks to analyze the burden of breast cancer in Asia based on the most recent GLOBOCAN 2022 estimates.</div></div><div><h3>Methods</h3><div>Data were obtained from GLOBOCAN 2022. Age-standardized rates for incidence and mortality per 100,000 person-years were calculated using direct age standardization with the Segi-Doll World standard population. Pearson's correlation coefficient was utilized to evaluate the relationship between human development index and incidence or mortality rate. The future number of breast cancer cases and deaths by 2050 was estimated based on global demographic projections.</div></div><div><h3>Results</h3><div>In 2022, breast cancer accounted for 2296.8 thousand new cases and 666.1 thousand deaths worldwide. In Asia, an estimated 985.4 thousand new cases and 315.1 thousand deaths were reported, corresponding to age-standardized incidence and mortality rates of 34.3 and 10.5 per 100,000, respectively. Both incidence and mortality rates were notably higher among older individuals, especially in countries with high human development index. A positive correlation between human development index and incidence rates was observed, while mortality rates were highest in countries with low human development index. China and India are the leading contributors to both new cases and deaths, with projections indicating that by 2050, around 1.4 million new breast cancer cases and 0.5 million deaths are expected to occur in Asia.</div></div><div><h3>Conclusion</h3><div>Breast cancer is the most common cancer among women in Asia. Global collaboration is essential to reduce its growing burden, especially in low-HDI countries facing rising incidence and high mortality rates.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103835"},"PeriodicalIF":5.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study","authors":"Alfonso Cortés ,&nbsp;Elena López-Miranda ,&nbsp;Adela Fernández-Ortega ,&nbsp;Vicente Carañana ,&nbsp;Sonia Servitja ,&nbsp;Ander Urruticoechea ,&nbsp;Laura Lema-Roso ,&nbsp;Antonia Márquez ,&nbsp;Alexandros Lazaris ,&nbsp;Daniel Alcalá-López ,&nbsp;Leonardo Mina ,&nbsp;Petra Gener ,&nbsp;Jose Rodríguez-Morató ,&nbsp;Gabriele Antonarelli ,&nbsp;Antonio Llombart-Cussac ,&nbsp;José Pérez-García ,&nbsp;Javier Cortés","doi":"10.1016/j.breast.2024.103834","DOIUrl":"10.1016/j.breast.2024.103834","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline <em>BRCA1/2</em> mutations (g<em>BRCA1/2</em>mut).</div></div><div><h3>Methods</h3><div>NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC without <em>gBRCA1/2mut</em> and with HRD, who were treated with olaparib. The primary endpoint was clinical benefit rate (CBR) per RECIST v.1.1.</div></div><div><h3>Results</h3><div>Six of 114 patients were eligible and received olaparib. Median follow up was 8.5 months. CBR and overall response rate (ORR) were 50 % (95 % CI, 11.8–88.2).</div></div><div><h3>Conclusions</h3><div>The observed results could prompt further investigation.</div></div><div><h3>Trial</h3><div>ClinicalTrials.gov identifier NCT03367689.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103834"},"PeriodicalIF":5.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative reference values for breast cancer patients using the BREAST-Q","authors":"Charlotta Kuhlefelt ,&nbsp;Jussi P. Repo ,&nbsp;Veera Rasi ,&nbsp;Tuomo Meretoja ,&nbsp;Tiina Jahkola ,&nbsp;Susanna Kauhanen ,&nbsp;Pauliina Homsy","doi":"10.1016/j.breast.2024.103832","DOIUrl":"10.1016/j.breast.2024.103832","url":null,"abstract":"<div><h3>Introduction</h3><div>The BREAST-Q can be used to evaluate the health-related quality of life (HRQL) of breast cancer patients. Data interpretation is limited by the lack of previous reference values based solely on patients with a recent breast cancer diagnosis.</div></div><div><h3>Methods</h3><div>A total of 627 patients, all with newly diagnosed breast cancer, were asked to participate in the study. The BREAST-Q modules for mastectomy and breast-conserving surgery were used. The results for the scales were reported as mean with standard deviation (SD). The effect of patient characteristics, including age, body mass index (BMI), and ASA-classification on the HRQL were analyzed with multiple linear regression.</div></div><div><h3>Results</h3><div>In total, 315 patients (50.2 %) participated. The mean (SD) age was 60.3 (10.1) years. Mean scores (SD) were the following: Psychosocial Well-being 70.8 (15.0), Sexual Well-being 58.2 (15.1), Satisfaction with Breasts 59.9 (15.6), and Physical Well-being: Chest 81.7 (15.7). The psychosocial well-being, sexual well-being, and satisfaction with breasts were all similar compared to the normative mean scores of the scales. The physical well-being of the chest was lower than the normative mean value (p &lt; 0.001). Psychosocial well-being (p = 0.007), sexual well-being (p = 0.007), and satisfaction with breasts (p &lt; 0.001) were lower in patients with higher BMI. Younger patients reported lower physical well-being of the chest (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>This study established preoperative reference values for the BREAST-Q in breast cancer patients. This data can be used to evaluate the HRQL in breast cancer patients accurately.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103832"},"PeriodicalIF":5.7,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locoregional recurrence after neoadjuvant versus adjuvant chemotherapy based on tumor subtypes in patients with early-stage breast cancer: A multi-institutional retrospective cohort study","authors":"Jong-Ho Cheun ,&nbsp;Youngji Kwak ,&nbsp;Eunhye Kang ,&nbsp;Ji-Jung Jung ,&nbsp;Hong-Kyu Kim ,&nbsp;Han-Byoel Lee ,&nbsp;Kyung-Hun Lee ,&nbsp;Hyeong-Gon Moon ,&nbsp;Ki-Tae Hwang ,&nbsp;Yeon Hee Park ,&nbsp;Jeong Eon Lee ,&nbsp;Wonshik Han","doi":"10.1016/j.breast.2024.103828","DOIUrl":"10.1016/j.breast.2024.103828","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). We investigated whether the risk of LRR after NACT varies across tumor subtypes.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the medical records of women who underwent breast-conserving surgery for breast cancer at three institutions between January 1, 2004, and December 31, 2018. Patients received either NACT or adjuvant chemotherapy (ACT), followed by radiotherapy. LRR was analyzed according to the hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status using propensity score matching, log-rank test, and Cox regression analysis.</div></div><div><h3>Results</h3><div>Among 10,328 patients, 2479 (24.0 %) received NACT. Within the median follow-up of 84.5 (IQR, 35.1–118.5) months, the 10-year LRR-free survival rates were 94.5 % and 90.7 % for the ACT and NACT groups, respectively (hazard ratio: 2.04, 95 % confidence interval [CI]: 1.68–2.46, p &lt; 0.0001). NACT was significantly associated with higher LRR in the HR+/HER2− (hazard ratio: 2.52, 95 % CI: 1.83–3.46, p &lt; 0.0001) and HR−/HER2− (hazard ratio: 1.85, 95 % CI: 1.37–2.50, p &lt; 0.0001) subtypes. In the HR+/HER2− subtype, the elevated risk remained significant after propensity-score matching and Cox-regression analysis. However, NACT was not associated with LRR in the HR−/HER2− subtype after adjusting for other variables. Annual LRR pattern among the HR+/HER2− subtype showed the highest incidence in the early period of treatment.</div></div><div><h3>Conclusion</h3><div>Patients with the HR+/HER2− subtype showed an increased risk of LRR after NACT, while those with other subtypes showed comparable LRR-free survival.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103828"},"PeriodicalIF":5.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The “lows”: Update on ER-low and HER2-low breast cancer","authors":"Nicola Fusco ,&nbsp;Giuseppe Viale","doi":"10.1016/j.breast.2024.103831","DOIUrl":"10.1016/j.breast.2024.103831","url":null,"abstract":"<div><div>ER-low and HER2-low breast cancers have emerged as clinically significant subtypes that challenge traditional diagnostic categories and treatment paradigms. These subtypes, representing a spectrum of disease, exhibit distinct biological behaviors, therapeutic responses, and prognostic outcomes. HER2-low breast cancer, defined by low HER2 protein expression (IHC score of 1+ or 2+ without HER2 gene amplification), has achieved clinical significance, particularly following the DESTINY-Breast trials, which demonstrated the efficacy of trastuzumab deruxtecan (T-DXd) in the population of patients with advanced HER2-low disease. Similarly, ER-low breast cancer, characterized by low estrogen receptor expression (in 1%–10 % invasive tumor cells), poses unique challenges due to its intermediate biological behavior and uncertain response to endocrine therapies. The identification of these subtypes is further complicated by inconsistencies in testing methodologies, which can lead to misclassification and impact treatment decisions. As our understanding of these subtypes improves, the need for standardized diagnostic approaches and individualized therapeutic decisions becomes increasingly urgent. Ongoing research and collaboration between pathologists and oncologists are essential for refining diagnostic criteria and improving outcomes for patients with breast cancers characterized by low expression of these theragnostic biomarkers. This review aims to consolidate current knowledge on HER2-low and ER-low breast cancers, focusing on the challenges associated with their identification, the implications for treatment, and future directions in clinical management. By examining recent studies and interlaboratory assessments, this review emphasizes the critical need for accurate and reproducible testing and reporting, and for the development of tailored therapeutic strategies for these “low” expression cancers.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103831"},"PeriodicalIF":5.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes","authors":"Lu Sun ,&nbsp;Xiaomeng Jia ,&nbsp;Kainan Wang,&nbsp;Man Li","doi":"10.1016/j.breast.2024.103830","DOIUrl":"10.1016/j.breast.2024.103830","url":null,"abstract":"<div><div>Breast cancer has become the most prevalent malignant tumor worldwide and remains one of the leading causes of cancer-related mortality among women globally. The prognosis for patients with metastatic breast cancer remains poor, necessitating the exploration of novel therapeutic strategies to improve survival rates. In the era of precision medicine, antibody-drug conjugates (ADCs) have gained significant attention as a targeted therapeutic strategy in breast cancer treatment. ADCs, a relatively new treatment for breast cancer, deliver cytotoxic drugs (payloads), directly into the tumor space, turning chemotherapy into a targeted agent, which enables patients to experience significant improvements with manageable drug toxicity. For the treatment of breast cancer, there are three ADCs approved for breast cancer treatment: Trastuzumab emtansine (T-DM1), Trastuzumab Deruxtecan (T-Dxd) targeting HER-2, and Sacituzumab Govitecan (SG) targeting Trop-2. Recent clinical studies have demonstrated that the benefits of ADC therapies extend beyond HER2-positive breast cancer toinclude hormone receptor (HR)-positive breast cancer, triple-negative breast cancer (TNBC), and HER2-low expressing breast cancer. Notably, the DESTINY-Breast series of studies, particularly focusing on T-Dxd, encompass neoadjuvant, adjuvant, and multiple lines of therapy for advanced breast cancer. This marks the advent of a comprehensive ADC era in breast cancer treatment. This review summarizes the efficacy and adverse effects of ADC therapies that have completed or are currently undergoing phase I-III clinical trials. Additionally, it analyzes potential combination strategies to overcome ADC resistance, aiming to provide clinicians with a comprehensive clinical guide to the use of ADCs in breast cancer treatment.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103830"},"PeriodicalIF":5.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy","authors":"M.C. Van Maaren ,&nbsp;T.A. Hueting ,&nbsp;D.J.P. van Uden ,&nbsp;M. van Hezewijk ,&nbsp;L. de Munck ,&nbsp;M.A.M. Mureau ,&nbsp;P.A. Seegers ,&nbsp;Q.J.M. Voorham ,&nbsp;M.K. Schmidt ,&nbsp;G.S. Sonke ,&nbsp;C.G.M. Groothuis-Oudshoorn ,&nbsp;S. Siesling ,&nbsp;NABOR project group","doi":"10.1016/j.breast.2024.103829","DOIUrl":"10.1016/j.breast.2024.103829","url":null,"abstract":"<div><h3>Background</h3><div>Individual risk prediction of 5-year locoregional recurrence (LRR) and contralateral breast cancer (CBC) supports decisions regarding personalised surveillance. The previously developed INFLUENCE tool was rebuild, including a recent population and patients who received neoadjuvant systemic therapy (NST).</div></div><div><h3>Methods</h3><div>Women, surgically treated for nonmetastatic breast cancer, diagnosed between 2012 and 2016, were selected from the Netherlands Cancer Registry. Cox regression with restricted cubic splines was compared to Random Survival Forest (RSF) to predict five-year LRR and CBC risks. Separate models were developed for NST patients. Discrimination and calibration were assessed by 100x bootstrap resampling.</div></div><div><h3>Results</h3><div>In the non-NST and NST group, 49,631 and 10,154 patients were included, respectively. Age, mode of detection, histology, sublocalisation, grade, pT, pN, hormonal receptor status ± endocrine treatment, HER2 status ± targeted treatment, surgery ± immediate reconstruction ± radiation therapy, and chemotherapy were significant predictors for LRR and/or CBC in non-NST patients. For NST patients this was similar, but excluding (y)pT and (y)pN status, and including presence of ductal carcinoma in situ, axillary lymph node dissection and pathologic complete response.</div><div>For non-NST patients, the Cox and RSF models were integrated in the online tool with 5-year AUCs of 0.77 (95%CI:0.77–0.77) and 0.68 (95%CI:0.67–0.68)] for LRR and CBC prediction, respectively. For NST patients, the RSF model performed best (AUCs 0.77 (95%CI:0.76–0.78) and 0.73 (95%CI:0.69–0.76) for LRR and CBC, respectively). Regarding calibration, observed-predicted differences were all &lt;1 %.</div></div><div><h3>Conclusion</h3><div>This INFLUENCE 3.0 models showed moderate performance in LRR and CBC prediction. The models have been made available as online tool to enable clinical decision support regarding personalised follow-up.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103829"},"PeriodicalIF":5.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of male breast cancer in Klinefelter Syndrome and its proposed mechanisms","authors":"Benjamin Cook ,&nbsp;Sasha Nayar ,&nbsp;Simon Filson ,&nbsp;Tet Yap","doi":"10.1016/j.breast.2024.103827","DOIUrl":"10.1016/j.breast.2024.103827","url":null,"abstract":"<div><h3>Introduction</h3><div>Men with Klinefelter Syndrome (KS) have been previously reported to have an increased risk of Male Breast Cancer (MBC). This systematic review provides the latest information regarding the incidence of MBC in the KS population compared to the standard male population and identifies mechanisms by which MBC may develop in KS.</div></div><div><h3>Material and methods</h3><div>Several databases were searched including PubMed/MEDLINE and EMBASE between October 2023 and March 2024. The review was conducted in accordance with the latest Preferred Reporting Items for Systematic Reviews and Meta-analyses-guidelines and was registered in PROSPERO (CRD42024551110). Overall, 332 papers were identified for screening. Standardised incidence ratios (SIRs) were calculated in comparison to national incidence figures. Additionally, a literature review was conducted looking at potential MBC mechanisms in KS.</div></div><div><h3>Results</h3><div>Across Danish and British cohorts, incidence of MBC in KS was significantly higher than the general population: SIR 18.1 (95 % CI: 13.53 to 24.74), <em>p</em>&lt;<em>0.001</em>. Breast cancer rates in women are still far higher (68.50 per 100,000 woman-years). MBC mechanism in KS may involve decreased micro-RNA (MIR-3648 and MIR3647) expression, increased oestrogen/progesterone receptor expression and exogenous androgen use.</div></div><div><h3>Conclusions</h3><div>Rates of MBC are significantly raised in KS and a higher clinical suspicion of breast cancer should be considered when assessing men with KS. The true aetiology of MBC in KS, however, requires further research. There is a need for an accurate and up to date study of MBC incidence in KS to define the current risk.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103827"},"PeriodicalIF":5.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant denosumab for early breast cancer–Evidence and controversy","authors":"Laura Moretti ,&nbsp;Laura Richelmi ,&nbsp;Deborah Cosentini,&nbsp;Rebecca Pedersini,&nbsp;Salvatore Grisanti,&nbsp;Vito Amoroso,&nbsp;Alfredo Berruti,&nbsp;Marta Laganà","doi":"10.1016/j.breast.2024.103826","DOIUrl":"10.1016/j.breast.2024.103826","url":null,"abstract":"<div><div>The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103826"},"PeriodicalIF":5.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}